FDA approves first generic version of Roche's flu drug

The FDA approved the first generic version of Roche's Xofluza, a single-dose flu treatment for certain patients aged five years and older. The approval expands generic competition in the antiviral market and could pressure pricing for the branded product. The news is positive for access and competition, but the direct market impact is likely limited.

Analysis

The FDA approved the first generic version of Roche's Xofluza, a single-dose flu treatment for certain patients aged five years and older. The approval expands generic competition in the antiviral market and could pressure pricing for the branded product. The news is positive for access and competition, but the direct market impact is likely limited.